For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$55.76
Thesis
CRISPR Therapeutics commercialized one of the first approved CRISPR-based medicines and is extending editing into in vivo and immuno-oncology programs. An approved therapy plus a deep pipeline anchors a leading position in gene editing.
Catalysts
- Casgevy commercial ramp and patient starts
- In vivo editing program readouts
- Cell-therapy and cardiovascular pipeline progress
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Sep 22Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease.
- Sep 18Trial initiationClinicalTrials.gov
CRISPR Therapeutics Phase 1 trial NCT07491172 for CTX310 in refractory dyslipidemias begins recruiting.
- Sep 15Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1 trial NCT07491172 evaluating CTX310 in refractory dyslipidemias; status recruiting.
- Sep 9Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1 trial of CTX310 for refractory dyslipidemias (NCT07491172).
- Aug 11Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1/2 trial (NCT07758634) of CTX340 for hypertension; status recruiting as of 2026-08-11.
- Aug 3Financial resultsSEC
CRISPR Therapeutics AG filed 8-K with items 2.02 and 9.01 on 2026-08-03.
- Jul 23Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1 safety trial of CTX310 for refractory dyslipidemias (NCT07491172).
- Jul 22Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease; status recruiting.